Analyst Research

Report Title Price
Provider: Reuters Investment Profile
Provider: GlobalData
Provider: Wright Reports
Provider: Thomson Reuters StreetEvents

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Alk Abello A/S Announces Positive Results from Phase III Trails of Allergy Immunotherapy Tablet

Thursday, 11 Jul 2013 02:58am EDT 

Alk Abello A/S announced the positive top-line results from the pivotal Phase III MITRA trial conducted with ALK’s allergy immunotherapy tablet against house dust mite-induced respiratory diseases. The results demonstrate that the treatment significantly reduces patients’ risks of moderate to severe asthma exacerbations. The results were statistically significant (p<0.05). The trial also demonstrated that the treatment was well tolerated and had a favorable safety profile. The MITRA trial (MT-04) was initiated by ALK in 2011 to evaluate the efficacy and safety of the allergy immunotherapy tablet compared to placebo in patients with house dust mite-induced asthma. The primary endpoint of the trial was reduction in the risk of moderate to severe asthma exacerbations during steroid reduction as measured by the time to the first exacerbation. The trial was a randomized, placebo-controlled, double-blind, multi-center trial involving 834 patients from 13 European countries. Patients were divided into three treatment arms. Patients in the first two groups received two different doses of the tablet, while patients in the third group received placebo. Patients were dosed once daily for up to 18 months. Additionally, all patients received treatment with inhaled corticosteroids (ICS) until the last part of the trial, where the ICS usage was reduced by 50% for three months, and then completely withdrawn for another three months. 

Company Quote

30 Oct 2014